Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Research Article
  • Published:

Significant dissociation of brain and plasma kinetics with antipsychotics

Molecular Psychiatry volume 7, pages 317–321 (2002)Cite this article

Abstract

Current dosing regimens of psychotropic drugs are based on plasma kinetic considerations, although it is unclear whether plasma levels faithfully reflect brain kinetics of drugs.1,2 To examine this, we compared the kinetics of plasma levels of two widely used antipsychotics, olanzapine and risperidone, vs the time course of their effects in the brain. We used positron emission tomography (PET) and [11C]-labeled ligands to quantify striatal and extra-striatal dopamine-2 (D2), and cortical serotonin-2A (5-HT2A) receptor occupancy in healthy subjects after a single dose, and in patients chronically treated for psychosis. We found a significant dissociation of brain and plasma kinetics. Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D2 receptor occupancy. We found similar discrepancies between the time course of plasma levels and extra-striatal D2 as well as 5-HT2A receptor occupancy. Our results question the current reliance on plasma kinetics as the main basis for dosing regimens of antipsychotics. Studies of brain kinetics may provide a sounder basis for determining dosing schedules of psychotropic medications.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Farde L, Wiesel FA, Halldin C, Sedvall G . Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs Arch Gen Psychiatry 1988 45: 71–76

    Article  CAS  PubMed  Google Scholar 

  2. Gifford AN, Gatley SJ, Volkow ND . Evaluation of the importance of rebinding to receptors in slowing the approach to equilibrium of high-affinity PET and SPECT radiotracers Synapse 1998 28: 167–175

    Article  CAS  PubMed  Google Scholar 

  3. Seeman P, Lee T, Chau-Wong M, Wong K . Antipsychotic drug doses and neuroleptic/dopamine receptors Nature 1976 261: 717–719

    Article  CAS  PubMed  Google Scholar 

  4. Seeman P, Tallerico T, Corbett R, Van Tol HH, Kamboj RK . Role of dopamine D2, D4 and serotonin(2A) receptors in antipsychotic and anticataleptic action J Psychopharmacol 1997 11: 15–17

    Article  CAS  PubMed  Google Scholar 

  5. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding Psychopharmacol (Berl) 1996 124: 57–73

    Article  CAS  Google Scholar 

  6. Nyberg S, Farde L, Halldin C . A PET study of 5-HT2 and D2 dopa-mine receptor occupancy induced by olanzapine in healthy subjects Neuropsychopharmacology 1997 16: 1–7

    Article  CAS  PubMed  Google Scholar 

  7. Kapur S, Zipursky RB, Remington G . Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia Am J Psychiatry 1999 156: 286–293

    CAS  PubMed  Google Scholar 

  8. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels Psychopharmacology 1989 99: 463–472

    Article  CAS  PubMed  Google Scholar 

  9. Nyberg S, Farde L, Halldin C . Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings Arch Gen Psychiatry 1997 54: 953–958

    Article  CAS  PubMed  Google Scholar 

  10. Farde L, Suhara T, Nyberg S, Karlsson P, Nakashima Y, Hietala J et al. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients Psychopharmacol (Berl) 1997 133: 396–404

    Article  CAS  Google Scholar 

  11. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM . Olanzapine. Pharmacokinetic and pharmacodynamic profile Clin Pharmacokinet 1999 37: 177–193

    Article  CAS  PubMed  Google Scholar 

  12. Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L et al. The pharmacokinetics of risperidone in humans: a summary J Clin Psychiatry 1994 55 Suppl: 13–17

    CAS  PubMed  Google Scholar 

  13. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects Clin Pharmacol Ther 1993 54: 257–268

    Article  CAS  PubMed  Google Scholar 

  14. Borison RL, Diamond B, Pathiraja A, Meibach RC . Pharmacokinetics of risperidone in chronic schizophrenic patients Psychopharmacol Bull 1994 30: 193–197

    CAS  PubMed  Google Scholar 

  15. Meltzer HY, Matsubara S, Lee JC . Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values J Pharmacol Exp Ther 1989 251: 238–246

    CAS  PubMed  Google Scholar 

  16. Aravagiri M, Teper Y, Marder SR . Pharmacokinetics and tissue distribution of olanzapine in rats Biopharm Drug Dispos 1999 20: 369–377

    Article  CAS  PubMed  Google Scholar 

  17. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P . A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy Arch Gen Psychiatry 2000 57: 553–559

    Article  CAS  PubMed  Google Scholar 

  18. Nyberg S, Farde L, Halldin C, Dahl ML, Bertilsson L . D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate Am J Psychiatry 1995 152: 173–178

    Article  CAS  PubMed  Google Scholar 

  19. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients Acta Psychiatr Scand Suppl 1987 334: 1–100

    Article  CAS  PubMed  Google Scholar 

  20. Lammertsma AA, Hume SP . Simplified reference tissue model for PET receptor studies Neuroimage 1996 4: 153–158

    Article  CAS  PubMed  Google Scholar 

  21. Berna M, Shugert R, Mullen J . Determination of olanzapine in human plasma and serum by liquid chromatography/tandem mass spectrometry J Mass Spectrom 1998 33: 1003–1008

    Article  CAS  PubMed  Google Scholar 

  22. Woestenborghs R, Lorreyne W, Van Rompaey F, Heykants J . Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography J Chromatogr 1992 583: 223–230

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the patients and the volunteers for their participation: Doug Hussey, Kevin Cheung, Jenny Li and Armando Garcia for technical assistance; Barb Brownlee for critical review of the manuscript; and Dr Alan Wilson for supervising the radiochemical syntheses. The research was supported in part by a grant from Eli Lilly Canada. Astra Zeneca provided the precursor used in the synthesis of [11C]raclopride.

Author information

Authors and Affiliations

  1. Schizophrenia-PET Program, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada

    J Tauscher, C Jones & S Kapur

  2. Schizophrenia and Continuing Care Program, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada

    J Tauscher, G Remington, R B Zipursky & S Kapur

  3. Department of Psychiatry, University of Toronto, Toronto, Canada

    G Remington, R B Zipursky & S Kapur

  4. Department of General Psychiatry, University of Vienna, Vienna, Austria

    J Tauscher

Authors
  1. J Tauscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Remington
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R B Zipursky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Kapur
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Tauscher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tauscher, J., Jones, C., Remington, G. et al. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7, 317–321 (2002). https://doi.org/10.1038/sj.mp.4001009

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.mp.4001009

Keywords

This article is cited by

Search

Advanced search

Quick links